Experimental CAR-T therapy targets stubborn tumors in tiny trial
NCT ID NCT07108140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new type of immune cell therapy called ALPP CAR-T cells in 5 people with advanced solid tumors that had stopped responding to other treatments. The therapy was designed to target a protein called ALPP found on the surface of some tumor cells. The study was terminated early, but its main goal was to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-ALPP CAR-T cells (a type of immune cell therapy) given after chemotherapy drugs fludarabine and cyclophosphamide
- What this could lead to
- If it works, this could point toward a new treatment option for certain hard-to-treat solid tumors that express ALPP.
- What could go wrong
- This was a very early, small pilot study that was terminated early. It may not show clear benefit, and CAR-T cell therapy can cause severe side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Jinling Hospital
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?